AU2017316614B2 - Nicotinamide riboside and pterostilbene compositions and methods for treatment of neurodegenerative disorders - Google Patents

Nicotinamide riboside and pterostilbene compositions and methods for treatment of neurodegenerative disorders Download PDF

Info

Publication number
AU2017316614B2
AU2017316614B2 AU2017316614A AU2017316614A AU2017316614B2 AU 2017316614 B2 AU2017316614 B2 AU 2017316614B2 AU 2017316614 A AU2017316614 A AU 2017316614A AU 2017316614 A AU2017316614 A AU 2017316614A AU 2017316614 B2 AU2017316614 B2 AU 2017316614B2
Authority
AU
Australia
Prior art keywords
pterostilbene
composition
nicotinamide riboside
substituted
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017316614A
Other languages
English (en)
Other versions
AU2017316614A1 (en
Inventor
Daniel Antonio Alminana
Eric Alexander Marcotulli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elysium Health Inc
Original Assignee
Elysium Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elysium Health Inc filed Critical Elysium Health Inc
Publication of AU2017316614A1 publication Critical patent/AU2017316614A1/en
Application granted granted Critical
Publication of AU2017316614B2 publication Critical patent/AU2017316614B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
AU2017316614A 2016-08-22 2017-08-22 Nicotinamide riboside and pterostilbene compositions and methods for treatment of neurodegenerative disorders Active AU2017316614B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662378053P 2016-08-22 2016-08-22
US62/378,053 2016-08-22
PCT/US2017/047979 WO2018039207A1 (en) 2016-08-22 2017-08-22 Nicotinamide riboside and pterostilbene compositions and methods for treatment of neurodegenerative disorders

Publications (2)

Publication Number Publication Date
AU2017316614A1 AU2017316614A1 (en) 2019-03-21
AU2017316614B2 true AU2017316614B2 (en) 2023-06-15

Family

ID=61246253

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017316614A Active AU2017316614B2 (en) 2016-08-22 2017-08-22 Nicotinamide riboside and pterostilbene compositions and methods for treatment of neurodegenerative disorders

Country Status (12)

Country Link
US (2) US11260069B2 (https=)
EP (1) EP3500267A4 (https=)
JP (1) JP7132907B2 (https=)
KR (1) KR20190046895A (https=)
CN (2) CN115645432A (https=)
AU (1) AU2017316614B2 (https=)
BR (1) BR112019003579A2 (https=)
CA (1) CA3034673A1 (https=)
MX (1) MX2019002211A (https=)
RU (1) RU2019108100A (https=)
WO (1) WO2018039207A1 (https=)
ZA (1) ZA201901536B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019003579A2 (pt) 2016-08-22 2019-05-21 Elysium Health, Inc. Composições de ribosídeo de nicotinamida e pterostilbeno e métodos para o tratamento dedistúrbios neurodegenerativos
US20200085849A1 (en) * 2017-05-18 2020-03-19 Elysium Health, Inc. Methods and compositions for improving sleep
EP3642214A2 (en) 2017-06-19 2020-04-29 Gangadhara Ganapati Nicotinamide riboside derivatives and their uses
CA3108015A1 (en) * 2017-07-28 2019-01-31 Centers For Age Control, Inc. Compositions and methods for preventing and reversing aspects of aging
WO2020081923A1 (en) * 2018-10-19 2020-04-23 Disarm Therapeutics, Inc. Inhibitors of sarm1 in combination with nad+ or a nad+ precursor
WO2020102326A1 (en) * 2018-11-13 2020-05-22 Elysium Health, Inc Methods for determining and increasing nad levels
EP3897666A2 (en) 2018-12-17 2021-10-27 Mitopower LLC Nicotinyl riboside compounds and their uses
US12350283B2 (en) 2019-02-26 2025-07-08 Universitat De Valencia-Estudi General Methods and compositions for treating motor neuron diseases
CN110812365A (zh) * 2019-11-07 2020-02-21 明特奇点医疗科技（北京）有限公司 一种组合物及其制备方法与制剂
CN111838669B (zh) * 2020-08-07 2022-11-29 四川大学华西医院 治疗改善易损脏器的纳米组合物、制剂及制备方法和用途
EP4029496A1 (en) * 2021-01-18 2022-07-20 Universitat de València Pterostilbene and silibinin for preventing, ameliorating or reducing radiation-induced diseases
EP4079311B1 (en) 2021-04-20 2025-10-01 Nuvamid SA Nmn and derivatives for use in the treatment of depression and/or anxiety in patients having a form of parkinsonism
EP4284387B1 (en) 2021-06-24 2024-07-31 Vestlandets Innovasjonsselskap As (Vis) Nad-augmentation therapy for parkinson's disease
WO2022269064A1 (en) * 2021-06-24 2022-12-29 Vestlandets Innovasjonsselskap As (Vis) Nad-augmentation therapy for parkinson's disease
CN118176006A (zh) * 2021-10-27 2024-06-11 益力舒健康公司 治疗更年期综合征的方法
WO2024259359A2 (en) 2023-06-14 2024-12-19 ChromaDex Inc. Nicotinamide riboside and derivatives thereof in intravenous formulations and methods of use thereof
CN116807985A (zh) * 2023-06-20 2023-09-29 风火轮(上海)生物科技有限公司 一种烟酰胺核糖组合物及其制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008501343A (ja) * 2004-06-04 2008-01-24 ワシントン・ユニバーシティ 神経障害を治療するための方法および組成物
EP2574339A1 (de) * 2011-09-27 2013-04-03 Johannes Huber Pharmazeutisches Präparat zur Behandlung von NADH-bedingten Erkrankungen
WO2015066382A1 (en) * 2013-10-30 2015-05-07 ChromaDex Inc. Nicotinamide riboside compositions for topical use in treating skin conditions
WO2016122832A1 (en) * 2015-01-30 2016-08-04 Natural Formulations Compositions, therapeutic and prophylactic methods for treatment of neurodegenerative diseases and brain injuries
WO2016149277A1 (en) * 2015-03-17 2016-09-22 Specialty Nutrition Group, Inc. Nutritional compositions to enhance mitochondrial energy production

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2805719A1 (en) 2005-03-30 2014-11-26 Glaxosmithkline LLC Nicotinamide riboside and analogues thereof
US20090069444A1 (en) * 2007-09-07 2009-03-12 The United States Of America, As Represented By Th E Secretary Of Agriculture Method to Ameliorate Oxidative Stress and Improve Working Memory Via Pterostilbene Administration
WO2009082459A2 (en) * 2007-12-24 2009-07-02 Natrol, Inc. Anti-aging composition containing resveratrol and method of administration
WO2010095926A1 (en) 2009-02-20 2010-08-26 N.V. Nutricia Use of reveratrol for preserving cognitive functioning
ES2798254T3 (es) 2009-06-22 2020-12-10 Indus Biotech Private Ltd Proceso para la obtención de pteroestilbeno purificado y métodos de uso del mismo
EP2456772A4 (en) 2009-07-24 2013-02-27 Amazentis Sa COMPOUNDS, COMPOSITIONS AND METHODS FOR CONSERVING HEALTH HEALTH IN NEURODEEGENERATIVE DISEASES
US9439875B2 (en) 2011-05-11 2016-09-13 The United States Of America, As Represented By The Secretary Of Agriculture Anxiolytic effect of pterostilbene
US20130149277A1 (en) 2011-12-13 2013-06-13 Cliffstar Llc Pterostilbene and pvp grape juice extract combination for treatment of metabolic, vascular, and neurodegenerative disorders
US20130296440A1 (en) 2012-05-01 2013-11-07 ChromaDex Inc. Pterostilbene and curcumin combination for treatment of oxidative stress and inflammation
KR20170012449A (ko) 2014-06-02 2017-02-02 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 결정질 베타-d-니코틴아미드 리보시드의 제조 및 용도
BR112019003579A2 (pt) 2016-08-22 2019-05-21 Elysium Health, Inc. Composições de ribosídeo de nicotinamida e pterostilbeno e métodos para o tratamento dedistúrbios neurodegenerativos

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008501343A (ja) * 2004-06-04 2008-01-24 ワシントン・ユニバーシティ 神経障害を治療するための方法および組成物
EP2574339A1 (de) * 2011-09-27 2013-04-03 Johannes Huber Pharmazeutisches Präparat zur Behandlung von NADH-bedingten Erkrankungen
WO2015066382A1 (en) * 2013-10-30 2015-05-07 ChromaDex Inc. Nicotinamide riboside compositions for topical use in treating skin conditions
WO2016122832A1 (en) * 2015-01-30 2016-08-04 Natural Formulations Compositions, therapeutic and prophylactic methods for treatment of neurodegenerative diseases and brain injuries
WO2016149277A1 (en) * 2015-03-17 2016-09-22 Specialty Nutrition Group, Inc. Nutritional compositions to enhance mitochondrial energy production

Also Published As

Publication number Publication date
JP7132907B2 (ja) 2022-09-07
JP2019524856A (ja) 2019-09-05
RU2019108100A3 (https=) 2020-11-27
ZA201901536B (en) 2024-06-26
MX2019002211A (es) 2019-10-30
AU2017316614A1 (en) 2019-03-21
KR20190046895A (ko) 2019-05-07
US11260069B2 (en) 2022-03-01
CA3034673A1 (en) 2018-03-01
CN109982706A (zh) 2019-07-05
WO2018039207A1 (en) 2018-03-01
RU2019108100A (ru) 2020-09-22
BR112019003579A2 (pt) 2019-05-21
CN115645432A (zh) 2023-01-31
EP3500267A4 (en) 2020-03-18
EP3500267A1 (en) 2019-06-26
US20220143055A1 (en) 2022-05-12
US20190201426A1 (en) 2019-07-04
US11998561B2 (en) 2024-06-04

Similar Documents

Publication Publication Date Title
US11998561B2 (en) Nicotinamide riboside and pterostilbene compositions and methods for treatment of neurodegenerative disorders
AU2020286208B2 (en) Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders
CA3105341C (en) Methods of normalizing amino acid metabolism
EP3185859B1 (en) New therapeutic approaches for treating parkinson's disease
WO2012142413A2 (en) Nitrite compositions and uses thereof
JP6420797B2 (ja) 活動意欲向上剤
JP2017036271A5 (https=)
HK1254169B (en) Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders
HK1254169A1 (en) Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders
BR112017026642B1 (pt) Composições de ribosídeo de nicotinamida e pteroestilbeno e seus usos
HK40052619A (en) Methods of normalizing amino acid metabolism

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)